<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718497</url>
  </required_header>
  <id_info>
    <org_study_id>Internal-17018</org_study_id>
    <nct_id>NCT00718497</nct_id>
  </id_info>
  <brief_title>Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population</brief_title>
  <official_title>Comparing The Cyberlink Control System to the Manual Letter Board for Communication Purposes in the ALS Patient Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drexel University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MDA/ALS Center of Hope</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drexel University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New technologies are giving people with motor disabilities alternative communication and
      control channels. The investigators are interested in using the Cyberlink Control System as a
      hands free means to access a computer for people with Amyotrophic Lateral Sclerosis (ALS).
      The goal of this project is to determine whether this device is a practical and realistic
      means for ALS patients to communicate with only the use of facial muscle, brainwave, and eye
      movements.

      The benefit of this study may be of substantial value to many people with severe motor
      impairment. Additionally, it is hoped that some of the study subjects may benefit by
      incorporating hands-free computer use into their daily lives.

      This study is intended to evaluate the effectiveness of the cyberlink as a tool for daily
      communication compared to the standard manual letter board.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time Taken to Complete a Sentence</measure>
    <time_frame>1 session</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">25</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Neurodegenerative Disease</condition>
  <condition>Motor Neuron Disease</condition>
  <arm_group>
    <arm_group_label>ALS</arm_group_label>
    <description>Subjects having either definite or probable ALS by El Escorial Criteria.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        ALS clinic patients at MDA/ALS Center of Hope.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of definite or possible ALS by the El Escorial Criteria

          -  Between ages of 18 to 89 years.

          -  Scored two or less in the ALS FRS category 1 (Speech)

          -  Scored two or less in the ALS FRS category 4 (Handwriting)

          -  Cognitively intact with no other neurological diseases

          -  No unstable medical problems

        Exclusion Criteria:

          -  Any subject not meeting the inclusion criteria

          -  Patients unable to give informed consent either themselves or via a legally authorized
             personnel.

          -  Patients diagnosed with neurological problems other than ALS (upon examination by the
             principal investigator)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry Heiman-Patterson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDA/ALS Center of Hope</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDA/ALS Center of Hope</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>March 1, 2013</last_update_submitted>
  <last_update_submitted_qc>March 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Cerebrospinal Fluid</keyword>
  <keyword>Neurodegenerative Disease</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Autonomic Nervous System</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Movement Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

